Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT – Free Report) shares are going to reverse split on the morning of Monday, June 22nd. The 1-10 reverse split was announced on Wednesday, June 17th. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, June 19th.
Lakewood-Amedex Biotherapeutics Price Performance
NASDAQ LABT traded down $0.13 during trading on Thursday, hitting $0.47. The company’s stock had a trading volume of 367,954 shares, compared to its average volume of 2,699,963. Lakewood-Amedex Biotherapeutics has a fifty-two week low of $0.42 and a fifty-two week high of $9.82.
Analysts Set New Price Targets
Separately, Wall Street Zen cut Lakewood-Amedex Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th.
Lakewood-Amedex Biotherapeutics Company Profile
We are a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others. Antimicrobial resistance (AMR) represents a growing global health crisis, being directly responsible for 1.27 million deaths annually and contributing to nearly 5 million deaths worldwide.
Read More
- Five stocks we like better than Lakewood-Amedex Biotherapeutics
- 3 Hotel REITs Poised to Benefit from the World Cup
- Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story
- 3 Stocks Doing the Heavy Lifting in Healthcare’s Rebound
- Why BitMine’s Selloff May Be Missing the Bigger Story
Receive News & Ratings for Lakewood-Amedex Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lakewood-Amedex Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
